Insulin Analog 1 Diabetes Market Size, Share, Trends, Growth and Forecast 2032

Insulin Analog 1 Diabetes Market

Insulin Analog 1 Diabetes Market By Insulin Analog (Rapid-Acting Insulin Analogs, Long-Acting Insulin Analogs [Aspart, Glulisine, and Lyspro], and Premix Insulin Analogs), and by Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2024 - 2032

Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2920 Published Date: Oct-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 5.96 Billion USD 8.53 Billion 4.2% 2023

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
    • 2.2. Insulin Analog 1 Diabetes Market: Snapshot
  • Chapter 3. Insulin Analog 1 Diabetes Market – Industry Analysis
    • 3.1. Insulin Analog 1 Diabetes Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Rising prevalence of type-1 diabetes due to environmental and genetic factors
      • 3.2.2. Government support for the treatment of type-1 diabetes
    • 3.3. Restraints
      • 3.3.1. Stringent approvals process that varies from nation to nation
    • 3.4. Opportunities
    • 3.5. Porter’s Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis by Insulin Analog
      • 3.6.2. Market attractiveness analysis by Region
  • Chapter 4. Insulin Analog 1 Diabetes Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Insulin Analog 1 Diabetes Market: company market share, 2019
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New product launches
      • 4.2.3. Agreements, partnerships, cullaborations and joint ventures
      • 4.2.4. Research and development and regional expansion
  • Chapter 5. Global Insulin Analog 1 Diabetes Market – Insulin Analog Analysis
    • 5.1. Global Insulin Analog 1 Diabetes Market overview: by Insulin Analog
      • 5.1.1. Global Insulin Analog 1 Diabetes Market share, by Insulin Analog, 2019 and 2026
    • 5.2. Rapid-Acting Insulin Analogs
      • 5.2.1. Global Insulin Analog 1 Diabetes Market by Rapid-Acting Insulin Analogs, 2016 – 2026 (USD Million)
      • 5.2.2. Aspart
        • 5.2.2.1. Global Aspart in Insulin Analog 1 Diabetes Market by Rapid-Acting Insulin Analogs, 2016 – 2026 (USD Million)
      • 5.2.3. Glulisine
        • 5.2.3.1. Global Glulisine in Insulin Analog 1 Diabetes Market by Rapid-Acting Insulin Analogs, 2016 – 2026 (USD Million)
      • 5.2.4. Lyspro
        • 5.2.4.1. Global Lyspro in Insulin Analog 1 Diabetes Market by Rapid-Acting Insulin Analogs, 2016 – 2026 (USD Million)
    • 5.3. Long-Acting Insulin Analogs
      • 5.3.1. Global Insulin Analog 1 Diabetes Market by Long-Acting Insulin Analogs, 2016 – 2026 (USD Million)
    • 5.4. Premix Insulin Analogs
      • 5.4.1. Global Insulin Analog 1 Diabetes Market by Premix Insulin Analogs, 2016 – 2026 (USD Million)
  • Chapter 6. Global Insulin Analog 1 Diabetes Market - Regional Analysis
    • 6.1. Global Insulin Analog 1 Diabetes Market overview: by Region
      • 6.1.1. Global Insulin Analog 1 Diabetes Market share, by Region, 2019 and 2026
    • 6.2. North America
      • 6.2.1. North America Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
      • 6.2.2. North America Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
      • 6.2.3. North America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.2.4. U.S.
        • 6.2.4.1. U.S. Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.2.5. Rest of North America
        • 6.2.5.1. Rest of North America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
    • 6.3. Europe
      • 6.3.1. Europe Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
      • 6.3.2. Europe Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
      • 6.3.3. Europe Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.3.4. U.K.
        • 6.3.4.1. U.K. Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.3.5. France
        • 6.3.5.1. France Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.3.6. Germany
        • 6.3.6.1. Germany Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.3.7. Rest of Europe
        • 6.3.7.1. Rest of Europe Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
      • 6.4.2. Asia Pacific Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
      • 6.4.3. Asia Pacific Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.4.4. China
        • 6.4.4.1. China Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.4.5. Japan
        • 6.4.5.1. Japan Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.4.6. India
        • 6.4.6.1. India Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.4.7. Rest of Asia Pacific
        • 6.4.7.1. Rest of Asia Pacific Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
    • 6.5. Latin America
      • 6.5.1. Latin America Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
      • 6.5.2. Latin America Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
      • 6.5.3. Latin America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.5.4. Brazil
        • 6.5.4.1. Brazil Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.5.5. Rest of Latin America
        • 6.5.5.1. Rest of Latin America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
    • 6.6. The Middle East and Africa
      • 6.6.1. The Middle East and Africa Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
      • 6.6.2. The Middle East and Africa Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
      • 6.6.3. The Middle East and Africa Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.6.4. GCC Countries
        • 6.6.4.1. GCC Countries Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.6.5. South Africa
        • 6.6.5.1. South Africa Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
      • 6.6.6. Rest of Middle East & Africa
        • 6.6.6.1. Rest of Middle East & Africa Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
  • Chapter 7. Company Profiles
    • 7.1. Eli Lilly and Company
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfolio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Bayer Pharmaceuticals
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfolio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. Sanofi
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfolio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Novo Nordisk
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfolio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. AstraZeneca Plc
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfolio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. XOMA Corp.
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfolio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. DiaVacs, Inc.
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfolio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. B. Braun Melsungen AG
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfolio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. Biodel, Inc.
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfolio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
    • 7.10. Macrogenics, Inc.
      • 7.10.1. Overview
      • 7.10.2. Financials
      • 7.10.3. Product Portfolio
      • 7.10.4. Business Strategy
      • 7.10.5. Recent Development
    • 7.11. Takeda Pharmaceutical
      • 7.11.1. Overview
      • 7.11.2. Financials
      • 7.11.3. Product Portfolio
      • 7.11.4. Business Strategy
      • 7.11.5. Recent Development

Table Of Figures

List of Figures

1. Market research process
2. Market research methodology
3. Global Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
4. Porter’s Five Forces Analysis
5. Global Insulin Analog 1 Diabetes Market attractiveness, by Insulin Analog
6. Global Insulin Analog 1 Diabetes Market attractiveness, by Region
7. Global Insulin Analog 1 Diabetes Market share, by Insulin Analog, 2019 and 2026
8. Global Insulin Analog 1 Diabetes Market by Rapid-Acting Insulin Analogs, 2016 – 2026 (USD Million)
9. Global Insulin Analog 1 Diabetes Market by Long-Acting Insulin Analogs, 2016 – 2026 (USD Million)
10. Global Insulin Analog 1 Diabetes Market by Premix Insulin Analogs, 2016 – 2026 (USD Million)
11. Global Insulin Analog 1 Diabetes Market share, by Region, 2019 and 2026
12. North America Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
13. Europe Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
14. Asia Pacific Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
15. Latin America Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)
16. The Middle East and Africa Insulin Analog 1 Diabetes Market, 2016 – 2026 (USD Million)


Table Of Tables

List of Tables

1. Global Insulin Analog 1 Diabetes Market: snapshot
2. Drivers of the Insulin Analog 1 Diabetes Market: impact analysis
3. Restraints of the Insulin Analog 1 Diabetes Market: impact analysis
4. North America Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
5. North America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
6. U.S. Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
7. Rest of North America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
8. Europe Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
9. Europe Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
10. U.K. Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
11. France Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
12. Germany Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
13. Rest of Europe Insulin Analog 1 Diabetes revenue, by Insulin Analog, 2016 – 2026 (USD Million)
14. Asia Pacific Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
15. China Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
16. Japan Insulin Analog 1 Diabetes revenue, by Insulin Analog, 2016 – 2026 (USD Million)
17. India Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
18. Rest of Asia Pacific Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
19. Latin America Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
20. Latin America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
21. Brazil Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
22. Rest of Latin America Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
23. The Middle East and Africa Insulin Analog 1 Diabetes Market revenue, by Country, 2016 – 2026 (USD Million)
24. The Middle East and Africa Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
25. GCC Countries Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
26. South Africa Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
27. Rest of Middle East and Africa Insulin Analog 1 Diabetes Market revenue, by Insulin Analog, 2016 – 2026 (USD Million)
 

Methodology

FrequentlyAsked Questions

Designed to more faithfully replicate the body's natural insulin, customized versions of human insulin intended for Type 1 diabetes are known as insulin analogues A chronic disorder, type 1 diabetes requires patients to rely on insulin treatment to control blood glucose levels since the pancreas generates either little or none.

One main driver of the market is the increasing number of people worldwide diagnosed with Type 1 diabetes. Demand for insulin analogues arises from more people needing insulin treatment to control their condition.

According to Zion Market Research, the global Insulin Analog 1 Diabetes Market was worth USD 5.96 Billion in 2023. The market is forecast to reach USD 8.53 Billion by 2032.

According to Zion Market Research, the global Insulin Analog 1 Diabetes Market a compound annual growth rate (CAGR) of 4.2% during the forecast period 2024-2032.

Regionally, the insulin analog 1 diabetes market is divided into Europe, Latin America, Asia Pacific, North America, and the Middle East and Africa.

Eli Lilly and Company, Bayer Pharmaceuticals, Sanofi, Novo Nordisk, AstraZeneca Plc, XOMA Corp., DiaVacs, Inc., B. Braun Melsungen AG, Biodel, Inc., Macrogenics, Inc., and Takeda Pharmaceutical among others

  • zion payment modes

List of Contents

Market InsightsInsulin Analog 1 DiabetesOverviewInsulin Analog 1 DiabetesMarket:Growth FactorsInsulin Analog 1 DiabetesSegmentationReport ScopeInsulin Analog 1 DiabetesMarket:Regional InsightsSome of the players of insulin analog 1 diabetes market included in report are -The report segments the global insulin analog 1 diabetes market into:

HappyClients